mCura pipeline
From Discovery to Impact: Our Therapeutic Pipeline
Pipeline
We are advancing a portfolio of targeted mRNA therapeutics designed to address immune and inflammatory diseases with high unmet medical need. Our pipeline spans early discovery through preclinical development, focusing on precision delivery and transformative outcomes for patients.
mCura1: kidney-targeted therapy for glomerulonephritis
Glomerulonephritis is a serious condition that can cause progressive kidney damage and ultimately lead to chronic kidney disease (CKD). It affects millions of people worldwide and often necessitates dialysis or kidney transplantation. Current therapies rely on broad immunosuppression, which carries a significant risk of side effects and fails to stop disease progression.
mCura1 is Mercurna’s pioneering mRNA-based therapeutic, designed to directly target the root cause of glomerular inflammation. Built on our proprietary LNP platform, mCura1 delivers mRNA payload to glomerular cells driving kidney inflammation. This enables localized and controlled expression of therapeutic proteins that restore immune balance and safeguard renal function.
Key Highlights:
- Mechanism: Targeted delivery of mRNA to cells driving glomerular inflammation
- Stage: Preclinical development with proof-of-concept data
- Prevent progression to CKD by reducing inflammation and preserving kidney health
